Form 13G CYCLERION THERAPEUTICS INC For: 7 May
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cyclerion Therapeutics Inc (CYCN)
The Cyclerion Therapeutics share price today is 3.550, view NASDAQ CYCN stock exchange data. Track the latest Cyclerion Therapeutics share price with real-time updates on CYCN stock performance including market cap, day range, 52-week range and dividend yield. Access CYCN charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.399
3.690
52 wk Range
1.027
8.480
CYCN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.3993.690
52 wk Range
1.0278.480
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CYCN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Cyclerion to merge with Korsana in $380 million deal- Investing.com
- Form 13G CYCLERION THERAPEUTICS INC For: 7 May
- Investing.com
- Cyclerion to merge with Korsana in $380 million deal
- Investing.com
- Form 8K Cyclerion Therapeutics Inc For: 6 January
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Earnings
Latest Release
12-05-2026
EPS / Forecast
-0.76 / --
Revenue / Forecast
-- / --
Compare CYCN to Peers and Sector
Metrics to compare | CYCN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCYCNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.2x | 5.8x | −0.4x | |
PEG Ratio | 0.02 | −0.34 | 0.00 | |
Price/Book | 3.0x | 3.9x | 2.6x | |
Price / LTM Sales | 7.9x | 4.2x | 3.0x | |
Upside (Analyst Target) | 125.4% | 83.6% | 51.8% | |
Fair Value Upside | Unlock | 19.1% | 7.2% | Unlock |
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Cyclerion Therapeutics (CYCN) Share Price Today?
The Cyclerion Therapeutics share price today is 3.550.
What is the current Cyclerion Therapeutics (CYCN) share price and day range?
As of 06-08-2026, the Cyclerion Therapeutics share price is 3.550, with a previous close of 3.550. The share price has ranged from 3.399 to 3.690 today, while the 52-week range spans from 1.027 to 8.480.
What Is the Cyclerion Therapeutics Market Cap?
As of today, Cyclerion Therapeutics market cap is 15.060M.
What Is the Cyclerion Therapeutics (CYCN) Share Price Target?
The average 12-month share price target for Cyclerion Therapeutics is 8.000, with a high estimate of 8 and a low estimate of 8. 0 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +125.35% Upside potential.
What Is Cyclerion Therapeutics's Earnings Per Share (TTM)?
The Cyclerion Therapeutics EPS (TTM) is -1.468.
From a Technical Analysis Perspective, Is CYCN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
What Stock Exchange Does Cyclerion Therapeutics Trade On?
Cyclerion Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Cyclerion Therapeutics?
The stock symbol for Cyclerion Therapeutics is "CYCN."
How Many Times Has Cyclerion Therapeutics Stock Split?
Cyclerion Therapeutics has split 1 times.
How Many Employees Does Cyclerion Therapeutics Have?
Cyclerion Therapeutics has 1 employees.
What Is the CYCN After Hours Price?
CYCN's last after hours stock price is 3.540, the stock has changed by -0.010, or -0.280%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.